Decnupaz (pivekimab sunirine-pvzy) is a CD123-directed antibody-drug conjugate (ADC) developed for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic cancer. The therapy delivers a potent cytotoxic payload directly to cancer cells that express CD123, helping to maximize antitumor activity while minimizing damage to healthy tissues.
Decnupaz, as a targeted therapy for BPDCN, provides new treatment options for patients with a disease that historically has been associated with poor outcomes and limited therapeutic options. Its precision-based design is a testament to the growing impact of antibody-drug conjugates in modern oncology and rare cancer treatment.
